Risk factors
Amgen (AMGN) risk factors
Item 1A of every Amgen Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors40 risks15 new2 dropped13 reworded
Amgen details extensive regulatory oversight and clinical trial processes across global markets. State-level price control laws and PBM consolidation create severe pricing pressure. R&D spending rose to $7.3 billion in 2025 to support 23 Phase 3 programs.
Filed Feb 13, 2026 - FY2024 10-K risk factors27 risks
Amgen faces heavy exposure to pricing pressure and reimbursement restrictions from government and commercial third-party payers like PBMs.
Filed Feb 14, 2025